



ASX ANNOUNCEMENT

11 March 2019

## Joint Cynata-University of Melbourne Study Receives Funding Under Victorian Medical Research Accelerator Fund

**Melbourne, Australia; 11 March 2019:** Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the successful outcome of a grant application submitted by the University of Melbourne for a study investigating advanced materials for the manufacturing and delivery of highly potent mesenchymal stem cells (MSCs). The study will focus on industrially scalable biomaterials that facilitate the expansion and delivery of MSCs and will use Cynata's proprietary Cymerus™ MSCs as the source cell therapeutic product. The award provided by the Victorian Medical Research Accelerator Fund is a cash award made to the University of Melbourne, supplemented by funds provided by the University. Cynata will contribute Cymerus MSCs for the study.

Dr Kilian Kelly, Cynata's Vice President, Product Development said "The materials being developed in this project hold great potential for improving both the manufacturing of cells for therapeutic purposes and their delivery to patients. As such, this could prove to be a highly impactful technology, both economically and clinically, and one that Cynata will be pleased to investigate for potential commercial use."

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, [rosa.smith@mcpartners.com.au](mailto:rosa.smith@mcpartners.com.au)  
Annie Starr, U.S. Media Contact, +1 973.768.2170 , [astarr@6degreespr.com](mailto:astarr@6degreespr.com)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD and critical limb ischemia. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, critical limb ischemia, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.